# Nucleotide Analogues: Structure, Mechanisms, and Applications ## Introduction to Nucleotide Analogues ### What is a Nucleotide Analogue? A nucleotide analogue is a synthetic or semi-synthetic molecule that structurally mimics a natural nucleotide—the building block of DNA and RNA. Natural nucleotides consist of three components: a nitrogenous base (adenine, guanine, cytosine, thymine, or uracil), a five-carbon sugar (deoxyribose in DNA, ribose in RNA), and one or more phosphate groups. Nucleotide analogues retain the overall architecture of this molecule but carry deliberate chemical modifications to one or more of these components. These modifications alter the molecule's behavior in biological systems, allowing it to interfere with nucleic acid metabolism, inhibit polymerases, or serve as detectable probes. The distinction between a nucleoside analogue and a nucleotide analogue is important. A nucleoside consists only of a base attached to a sugar, without phosphate groups. A nucleotide is a nucleoside with at least one phosphate group attached. Many drugs are administered as nucleoside analogues and are converted to their active nucleotide (triphosphate) form inside cells by cellular kinases. For example, the anti-HIV drug zidovudine (AZT) is a nucleoside analogue that must be phosphorylated three times within the cell to become the active nucleotide analogue AZT-triphosphate. ### Why Study Nucleotide Analogues? Nucleotide analogues occupy a central position in both medicine and [molecular biology](/blog/careers/molecular-biology). In clinical practice, they form the backbone of antiviral therapy for HIV, hepatitis B, herpesviruses, and SARS-CoV-2, and they are among the most widely used chemotherapeutic agents for cancer. In the laboratory, fluorescent nucleotide analogues enable real-time imaging of DNA synthesis, and dideoxy nucleotides are the foundation of Sanger DNA sequencing. Understanding how these molecules work requires a firm grasp of their structural differences from natural nucleotides, their mechanisms of enzyme inhibition, and the biological consequences of their incorporation into nucleic acids. This knowledge is essential for interpreting drug mechanisms, designing new therapeutics, and troubleshooting [molecular biology](/blog/careers/molecular-biology) experiments. ## Structural Basis of Nucleotide Analogues The structural diversity of nucleotide analogues arises from modifications to any of the three components of a nucleotide: the nitrogenous base, the sugar moiety, or the phosphate group. Each type of modification confers distinct properties. ### Modifications to the Nitrogenous Base Base-modified analogues retain the sugar-phosphate backbone of a natural nucleotide but carry altered bases. These alterations can involve substitution of functional groups, addition of bulky side chains, or replacement of entire ring systems. **Halogenated bases** are common in anticancer therapy. 5-Fluorouracil (5-FU) replaces the hydrogen at the C5 position of uracil with a fluorine atom. This small change dramatically alters the molecule's metabolism. Inside cells, 5-FU is converted to 5-fluoro-dUMP, which irreversibly inhibits thymidylate synthase, the enzyme that converts dUMP to dTMP. Without dTMP, cells cannot synthesize thymidine triphosphate (dTTP), and DNA replication stalls. **Base analogues with altered hydrogen bonding** include hypoxanthine (the base in inosine) and 2-aminopurine. 2-Aminopurine pairs with thymine like adenine but can also pair with cytosine, making it a potent mutagen. When incorporated into DNA, it causes transition mutations during subsequent replication rounds. **Bulkier modifications** include biotinylated or fluorescent bases used for detection. For example, Cy3- or Cy5-labeled dUTP derivatives carry fluorescent moieties attached to the C5 position of uracil via a linker arm. These modifications do not prevent base pairing but allow visualization of newly synthesized DNA. ### Modifications to the Sugar Moiety Sugar-modified analogues are among the most clinically important. The sugar ring (ribose or deoxyribose) can be altered at the 2′, 3′, or 4′ carbon positions. **Dideoxy nucleotides** lack hydroxyl groups at both the 2′ and 3′ carbons. The 3′-OH is essential for phosphodiester bond formation during DNA synthesis. When a dideoxy nucleotide is incorporated into a growing DNA strand, the absence of the 3′-OH prevents further chain elongation. This property is exploited in Sanger sequencing. **AZT (zidovudine)** contains an azido group (–N₃) at the 3′ position of the deoxyribose sugar instead of a hydroxyl group. Like dideoxy nucleotides, AZT causes chain termination when incorporated into DNA by HIV reverse transcriptase. **Acyclovir** is an acyclic nucleoside analogue—its sugar ring is opened, leaving only a partial chain. The lack of a complete sugar ring means that once incorporated, the DNA chain cannot be extended because the molecule lacks the equivalent of a 3′-OH in the correct orientation. **2′,3′-Didehydro-2′,3′-dideoxythymidine (d4T, stavudine)** has a double bond between the 2′ and 3′ carbons, creating a rigid, unsaturated sugar ring. It also lacks a 3′-OH and acts as a chain terminator. **Ribose-modified analogues** such as 2′-fluoro-2′-deoxy nucleotides are used in RNA interference and antisense therapies because the 2′-fluoro modification increases resistance to nucleases while maintaining base-pairing ability. ### Modifications to the Phosphate Group Phosphate-modified analogues alter the linkage between nucleotides or the number of phosphate groups. **Phosphorothioate nucleotides** replace one of the non-bridging oxygen atoms in the phosphate group with sulfur. This modification renders the internucleotide linkage resistant to nuclease degradation, making phosphorothioate oligonucleotides valuable in antisense therapy and PCR applications where nuclease resistance is required. **Methylene-bridged phosphonates** such as those in tenofovir contain a phosphonate group (C–P bond) instead of a phosphate ester (C–O–P bond). The phosphonate linkage is not recognized by cellular phosphatases, so the molecule persists in cells much longer than natural nucleotides. **Unnatural base pairs** represent an extreme case of phosphate and base modification. For example, the d5SICS–dNaM pair uses hydrophobic bases that pair via shape complementarity rather than hydrogen bonding, yet they are efficiently replicated by engineered polymerases. | Modification Site | Example | Key Structural Change | Primary Consequence | |---|---|---|---| | Base | 5-Fluorouracil | H→F at C5 of uracil | Inhibits thymidylate synthase | | Base | 2-Aminopurine | NH₂ at C2 of purine | Mis-pairing, mutagenesis | | Sugar | Dideoxycytidine (ddC) | Missing 2′ and 3′ OH | Chain termination | | Sugar | AZT | 3′-OH replaced by N₃ | Chain termination | | Sugar | Acyclovir | Open sugar ring | Chain termination | | Phosphate | Phosphorothioate | O→S in phosphate | Nuclease resistance | | Phosphate | Tenofovir | Phosphonate linkage | Metabolic stability | ## Mechanisms of Action: How Nucleotide Analogues Work Nucleotide analogues exert their biological effects through three principal mechanisms: chain termination, competitive inhibition of polymerases, and incorporation leading to mutagenesis. These mechanisms are not mutually exclusive; many analogues operate through more than one pathway. ### Chain Termination Chain termination occurs when an analogue is incorporated into a growing nucleic acid strand but lacks the chemical group required for the next phosphodiester bond formation. DNA polymerases catalyze nucleotidyl transfer by attacking the α-phosphate of an incoming deoxynucleoside triphosphate (dNTP) with the 3′-hydroxyl group of the growing strand. If the incorporated nucleotide lacks a 3′-OH, the polymerase cannot add the next nucleotide, and synthesis stops. The efficiency of chain termination depends on the polymerase's ability to discriminate between the analogue and the natural substrate. HIV reverse transcriptase incorporates AZT-triphosphate with relatively high efficiency because the enzyme's active site accommodates the azido group. In contrast, human DNA polymerase γ (mitochondrial polymerase) is less tolerant, which contributes to AZT's mitochondrial toxicity. Chain termination can be **obligate** or **non-obligate**. Obligate terminators, such as dideoxy nucleotides, always stop synthesis upon incorporation. Non-obligate terminators, such as certain arabinosyl nucleotides, slow but do not completely halt elongation, allowing occasional extension past the lesion. ### Competitive Inhibition of Polymerases Nucleotide analogues can inhibit polymerases without being incorporated. The triphosphate forms of many analogues compete with natural dNTPs for binding to the polymerase active site. If the analogue binds but is not incorporated, it acts as a competitive inhibitor, reducing the effective concentration of natural substrates. The inhibition constant (Ki) for an analogue depends on its structural similarity to the natural substrate. For example, acyclovir-triphosphate inhibits herpes simplex virus (HSV) DNA polymerase with a Ki approximately 100-fold lower than the Km for dGTP, meaning the analogue binds much more tightly than the natural substrate. This high-affinity binding, combined with the fact that acyclovir-triphosphate is a poor substrate for incorporation, makes it an effective inhibitor. Competitive inhibition is particularly important for **nucleotide analogue reverse transcriptase inhibitors** (NtRTIs) such as tenofovir. Tenofovir-diphosphate competes with dATP for binding to HIV reverse transcriptase. The selectivity of tenofovir for the viral enzyme over human polymerases is a key determinant of its clinical safety. ### Incorporation and Mutagenesis Some nucleotide analogues are incorporated into DNA or RNA but do not terminate synthesis. Instead, they introduce mutations during subsequent replication or transcription. This mechanism underlies the mutagenic activity of base analogues like 2-aminopurine and 5-bromouracil. 5-Bromouracil (5-BU) is a thymine analogue that can tautomerize between keto and enol forms. In its keto form, it pairs with adenine like thymine. In its enol form, it pairs with guanine. If 5-BU is incorporated opposite adenine and then tautomerizes before the next replication round, it will direct incorporation of guanine opposite itself. This results in an A:T to G:C transition mutation. Incorporation of analogues can also cause **futile cycling** in DNA repair pathways. When an analogue is incorporated and then excised by [Nucleotide Excision Repair](/knowledge/molecular-biology/nucleotide-excision-repair) or [base excision repair](/knowledge/molecular-biology/base-excision-repair), the repair process may repeatedly incorporate and excise the analogue, generating DNA strand breaks and triggering apoptosis. This mechanism contributes to the cytotoxicity of many anticancer nucleotide analogues. ## Common Nucleotide Analogues and Their Uses ### Antiviral Nucleotide Analogues **Acyclovir (Zovirax)** is the prototypical anti-herpesvirus drug. It is a guanosine analogue with an acyclic sugar. Acyclovir is selectively phosphorylated by the viral thymidine kinase encoded by HSV and varicella-zoster virus, but not by human thymidine kinase. This selectivity means that acyclovir-triphosphate accumulates only in virus-infected cells. Acyclovir-triphosphate inhibits the viral DNA polymerase and causes chain termination when incorporated. **Zidovudine (AZT, Retrovir)** was the first FDA-approved drug for HIV. It is a thymidine analogue with a 3′-azido group. AZT is phosphorylated by human thymidine kinase, but its triphosphate form selectively inhibits HIV reverse transcriptase over human DNA polymerases. The selectivity arises from the different active site geometries of the viral and human enzymes. **Tenofovir (Viread)** is a nucleotide analogue (not a nucleoside analogue) because it carries a phosphonate group that mimics a monophosphate. This allows tenofovir to bypass the first phosphorylation step, which is often rate-limiting for nucleoside analogues. Tenofovir-diphosphate inhibits HIV reverse transcriptase and hepatitis B virus polymerase. **Sofosbuvir (Sovaldi)** is a uridine nucleotide analogue used to treat hepatitis C virus (HCV). It contains a phosphoramidate prodrug moiety that facilitates cellular uptake and intracellular activation. The active metabolite, sofosbuvir-triphosphate, inhibits the HCV NS5B RNA-dependent RNA polymerase and causes chain termination. ### Anticancer Nucleotide Analogues **5-Fluorouracil (5-FU)** is a pyrimidine analogue used to treat colorectal, breast, and head and neck cancers. Its active metabolite, 5-fluoro-dUMP, forms a covalent complex with thymidylate synthase and its cofactor methylenetetrahydrofolate, irreversibly inhibiting the enzyme. This blocks dTMP synthesis, depleting dTTP pools and causing "thymineless death" in rapidly dividing cells. **Gemcitabine (Gemzar)** is a cytidine analogue with two fluorine atoms at the 2′ position of the sugar. Gemcitabine-triphosphate inhibits ribonucleotide reductase, depleting dNTP pools, and is also incorporated into DNA, causing masked chain termination. The incorporation of gemcitabine is followed by one additional nucleotide, after which the polymerase stalls. **Cytarabine (Ara-C)** is an arabinosyl cytosine analogue used primarily to treat acute myeloid leukemia. The arabinose sugar differs from ribose only in the stereochemistry at the 2′ carbon. Cytarabine-triphosphate inhibits DNA polymerase and is incorporated into DNA, causing chain termination. Its selectivity for leukemic cells is partly due to the high expression of deoxycytidine kinase in these cells, which phosphorylates cytarabine to its active form. ### Fluorescent and Labeled Analogues for Research **Fluorescent dNTPs** such as Cy3-dUTP, Cy5-dUTP, and Alexa Fluor-labeled nucleotides are used in microarray hybridization, fluorescence [in situ hybridization](/knowledge/molecular-biology/in-situ-hybridization) (FISH), and real-time PCR. These analogues carry a fluorophore attached to the base via a linker that does not interfere with base pairing. During PCR, the polymerase incorporates the labeled nucleotides into the amplified product, allowing detection. **Biotin-labeled nucleotides** (e.g., biotin-11-dUTP) are used for affinity purification of DNA or RNA. After incorporation, the biotin tag can be captured using streptavidin-coated beads. **Dideoxy nucleotides labeled with four different fluorophores** are the basis of automated Sanger sequencing. Each of the four dideoxy nucleotides (ddATP, ddTTP, ddGTP, ddCTP) carries a distinct fluorophore, allowing all four chain-termination reactions to be performed in a single tube. ## Nucleotide Analogues in Antiviral Therapy ### HIV Reverse Transcriptase Inhibitors HIV reverse transcriptase (RT) converts the viral RNA genome into double-stranded DNA. This enzyme lacks proofreading activity, making it error-prone and also making it a vulnerable target for nucleotide analogues. Two classes of RT inhibitors exist: nucleoside/nucleotide RT inhibitors (NRTIs/NtRTIs) and non-nucleoside RT inhibitors (NNRTIs). NRTIs such as AZT, lamivudine (3TC), and abacavir are administered as nucleoside prodrugs. They require intracellular phosphorylation to their active triphosphate forms. The first phosphorylation step, catalyzed by nucleoside kinases, is often rate-limiting. For example, AZT is phosphorylated by thymidine kinase 1, but the second phosphorylation step (AZT-monophosphate to AZT-diphosphate) is inefficient, requiring high intracellular concentrations of the monophosphate. NtRTIs such as tenofovir bypass the first phosphorylation step because they already carry a phosphonate group. Tenofovir-diphosphate competes with dATP for incorporation into the growing viral DNA. Once incorporated, tenofovir causes chain termination because it lacks a 3′-OH. Resistance to NRTIs arises through two main mechanisms. **Discrimination** mutations (e.g., M184V in RT) reduce the incorporation of the analogue while allowing incorporation of natural nucleotides. **Excision** mutations (e.g., thymidine analogue mutations TAMs) enhance the removal of the incorporated analogue from the chain-terminated DNA, allowing synthesis to resume. ### Herpesvirus DNA Polymerase Inhibitors Herpesviruses encode their own DNA polymerase, which is the target of acyclovir, valacyclovir, famciclovir, and ganciclovir. These drugs share a common mechanism: they are selectively activated by viral kinases and then inhibit the viral DNA polymerase. Acyclovir is activated by the HSV thymidine kinase, which phosphorylates it to acyclovir-monophosphate. Cellular kinases then add two more phosphates to form acyclovir-triphosphate. The triphosphate inhibits HSV DNA polymerase by two mechanisms: competitive inhibition with dGTP and chain termination after incorporation. Ganciclovir, used to treat cytomegalovirus (CMV) infections, is activated by the CMV UL97 kinase. Ganciclovir-triphosphate is a substrate for the CMV DNA polymerase and causes chain termination. Resistance to ganciclovir arises from mutations in UL97 that reduce phosphorylation or mutations in the viral DNA polymerase that reduce incorporation. ## Nucleotide Analogues in Cancer Treatment ### Antimetabolites in Chemotherapy Nucleotide analogues used in cancer therapy are classified as antimetabolites because they interfere with normal metabolic pathways. Their selectivity for cancer cells relies on the fact that cancer cells divide more rapidly than most normal cells and therefore have higher rates of DNA synthesis. However, this selectivity is relative, not absolute, which explains the toxicity of these drugs to rapidly dividing normal tissues such as bone marrow, intestinal epithelium, and hair follicles. The mechanism of action of anticancer nucleotide analogues varies: - **Thymidylate synthase inhibitors** (5-FU, capecitabine) block dTMP synthesis, depleting dTTP. - **Ribonucleotide reductase inhibitors** (gemcitabine, hydroxyurea) deplete all four dNTP pools. - **DNA polymerase inhibitors** (cytarabine, fludarabine) directly inhibit DNA synthesis. - **Incorporation into DNA** (gemcitabine, cytarabine) causes strand breaks and activates apoptosis. The activation of anticancer nucleotide analogues requires phosphorylation by deoxycytidine kinase (for cytidine analogues) or thymidine kinase (for thymidine analogues). Cancer cells that downregulate these kinases develop resistance to the drugs. ### Resistance Mechanisms Resistance to anticancer nucleotide analogues can arise through multiple mechanisms: 1. **Reduced activation**: Decreased expression or activity of deoxycytidine kinase reduces the conversion of cytarabine and gemcitabine to their active monophosphate forms. 2. **Increased degradation**: Elevated levels of cytidine deaminase, which converts cytarabine to the inactive uracil arabinoside, reduce drug efficacy. 3. **Altered target enzymes**: Mutations in thymidylate synthase that reduce binding of 5-fluoro-dUMP confer resistance to 5-FU. 4. **Increased dNTP pools**: Upregulation of ribonucleotide reductase increases the concentration of natural dNTPs, which compete with the analogue triphosphates for polymerase binding. 5. **Enhanced DNA repair**: Increased activity of [Nucleotide Excision Repair](/knowledge/molecular-biology/nucleotide-excision-repair) or [base excision repair](/knowledge/molecular-biology/base-excision-repair) removes incorporated analogues from DNA, allowing cells to survive. ## Nucleotide Analogues as Research Tools ### Sanger Sequencing and Dideoxy Nucleotides Sanger sequencing, developed by Frederick Sanger in 1977, relies on the chain-terminating property of dideoxy nucleotides. The method uses four separate reactions (or one reaction with four fluorescently labeled ddNTPs) in which DNA polymerase extends a primer in the presence of a mixture of natural dNTPs and a small proportion of ddNTPs. The key to Sanger sequencing is the ratio of dNTPs to ddNTPs. If the ddNTP concentration is too high, all strands terminate after only a few nucleotides. If it is too low, fragments become too long. A typical ratio is 100:1 dNTP:ddNTP, which produces fragments spanning a range of lengths. The reaction is run at 37°C for 30–60 minutes, and the products are separated by capillary electrophoresis. Modern automated sequencers use four different fluorophores, one for each ddNTP. The use of fluorescently labeled ddNTPs allows all four reactions to be multiplexed in a single tube, and the fluorescence signal at each fragment length identifies the terminal nucleotide. ### Fluorescent Analogues for Imaging Fluorescent nucleotide analogues enable real-time visualization of DNA synthesis in living cells. For example, **EdU (5-ethynyl-2′-deoxyuridine)** is a thymidine analogue containing an alkyne group. After incorporation into DNA, the alkyne can be reacted with an azide-tagged fluorophore using click chemistry. This approach is superior to the older BrdU (bromodeoxyuridine) method because it does not require [DNA denaturation](/knowledge/molecular-biology/dna-denaturation) for antibody access. **Fluorescent dNTPs** are also used in single-molecule sequencing technologies. In Pacific Biosciences SMRT sequencing, DNA polymerase incorporates fluorescently labeled nucleotides into a growing strand, and the fluorescence is detected in real time. The fluorophore is attached to the terminal phosphate rather than the base, so it is cleaved off during incorporation and does not interfere with strand elongation. **Quantum dot-labeled nucleotides** have been developed for ultrasensitive detection, though their large size limits their use in polymerase reactions. ## Common Pitfalls and Misconceptions ### Distinguishing Analogues from Natural Nucleotides A common error is confusing nucleotide analogues with natural nucleotides or with nucleosides. Natural nucleotides are the standard building blocks of nucleic acids: dATP, dTTP, dGTP, dCTP for DNA, and ATP, UTP, GTP, CTP for RNA. Nucleotide analogues are structurally similar but chemically distinct. They are not found in natural nucleic acids under normal conditions. Another confusion involves the terms "nucleoside" and "nucleotide." A nucleoside is a base plus a sugar. A nucleotide is a base plus a sugar plus one or more phosphates. Many drugs are nucleoside analogues (e.g., acyclovir, AZT) that must be phosphorylated inside cells to become active nucleotide analogues. The distinction matters because nucleoside analogues are not substrates for polymerases—only their triphosphate forms are. ### Understanding Chain Termination Students often assume that any nucleotide analogue that inhibits a polymerase must cause chain termination. This is incorrect. Many analogues inhibit polymerases through competitive inhibition without being incorporated. For example, acyclovir-triphosphate inhibits HSV DNA polymerase primarily through competitive inhibition with dGTP, and its incorporation is relatively inefficient. Another misconception is that chain termination always occurs immediately upon incorporation. Some analogues, such as gemcitabine, allow incorporation of one or more additional nucleotides before synthesis stalls. This is called "masked chain termination" and is mechanistically distinct from the immediate termination caused by dideoxy nucleotides. ### Understanding Selectivity and Toxicity The selectivity of nucleotide analogues for viral or cancer cells is relative, not absolute. AZT is selectively incorporated by HIV reverse transcriptase, but it also inhibits human [mitochondrial DNA](/blog/guides/mitochondrial-dna) polymerase γ, causing mitochondrial toxicity. This manifests as myopathy, peripheral neuropathy, and lactic acidosis in patients on long-term AZT therapy. Similarly, anticancer nucleotide analogues are toxic to all rapidly dividing cells, not just cancer cells. The therapeutic index—the ratio of toxic dose to effective dose—is narrow for many of these drugs. This is why chemotherapy causes side effects such as myelosuppression, mucositis, and alopecia. Students should also understand that resistance to nucleotide analogues is a major clinical problem. For HIV, resistance mutations in reverse transcriptase can reduce drug susceptibility by 10- to 100-fold. For cancer, resistance can develop through multiple mechanisms, including reduced drug activation, increased drug efflux, and altered target enzymes. ## Frequently Asked Questions ### What is a nucleotide analogue? A nucleotide analogue is a synthetic molecule that structurally resembles a natural nucleotide—a nitrogenous base attached to a sugar and one or more phosphate groups—but contains chemical modifications to the base, sugar, or phosphate. These modifications allow the analogue to interfere with nucleic acid metabolism, inhibit polymerases, or serve as detectable probes in research. ### What are some examples of nucleotide analogues? Common examples include acyclovir (anti-herpes), AZT (anti-HIV), tenofovir (anti-HIV and hepatitis B), sofosbuvir (anti-hepatitis C), 5-fluorouracil and gemcitabine (anticancer), and dideoxy nucleotides used in DNA sequencing. Fluorescently labeled nucleotides such as Cy3-dUTP are used in research. ### How do nucleotide analogues work? Nucleotide analogues work through three main mechanisms: chain termination (incorporation into a growing nucleic acid strand prevents further elongation), competitive inhibition (the analogue binds to a polymerase active site but is not incorporated, blocking access to natural substrates), and incorporation leading to mutagenesis (the analogue is incorporated but causes mispairing in subsequent replication rounds). ### Are nucleotide analogues natural? No. Nucleotide analogues are synthetic or semi-synthetic molecules. They are designed to mimic natural nucleotides but contain deliberate chemical modifications. Some analogues are derived from natural products, but the active compounds are not found in natural nucleic acids. ### Why are nucleotide analogues used in medicine? Nucleotide analogues are used in medicine because they can selectively inhibit viral or cancer cell polymerases while causing less harm to normal cells. They are used to treat HIV, hepatitis B and C, herpesvirus infections, and various cancers. Their selectivity arises from differences between viral and human enzymes, or from the higher replication rates of cancer cells. ### What is the difference between a nucleoside analogue and a nucleotide analogue? A nucleoside analogue consists of a base attached to a sugar but lacks phosphate groups. A nucleotide analogue includes at least one phosphate group. Many drugs are administered as nucleoside analogues and are converted to their active nucleotide triphosphate forms inside cells by kinases. For example, AZT is a nucleoside analogue that must be phosphorylated three times to become the active AZT-triphosphate. ### Can nucleotide analogues cause side effects? Yes. Nucleotide analogues can cause significant side effects because they are not perfectly selective. AZT can cause mitochondrial toxicity, leading to myopathy and lactic acidosis. Anticancer nucleotide analogues suppress bone marrow, causing anemia and increased infection risk. The severity of side effects depends on the drug, the dose, and the duration of treatment. ## Key Takeaways - Nucleotide analogues are synthetic molecules that mimic natural nucleotides but contain modifications to the base, sugar, or phosphate group. - The three principal mechanisms of action are chain termination, competitive inhibition of polymerases, and incorporation leading to mutagenesis. - Chain termination requires the absence of a 3′-hydroxyl group on the sugar, preventing phosphodiester bond formation. - Antiviral nucleotide analogues such as AZT and acyclovir exploit differences between viral and human enzymes to achieve selectivity. - Anticancer nucleotide analogues such as 5-fluorouracil and gemcitabine disrupt DNA synthesis in rapidly dividing cells but cause toxicity to normal dividing tissues. - Dideoxy nucleotides are the basis of Sanger DNA sequencing, while fluorescent nucleotide analogues enable real-time imaging of DNA synthesis. - Resistance to nucleotide analogues arises through reduced activation, increased degradation, altered target enzymes, and enhanced DNA repair. - The distinction between nucleoside and nucleotide analogues is critical: nucleosides require intracellular phosphorylation to become active. ## Further Reading - Fan J et al. *Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients*. The Journal of general virology. 2015. [PubMed 25481755](https://doi.org/10.1099/jgv.0.000010) - Hu J et al. *Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models*. Gut. 2026. [PubMed 41791851](https://doi.org/10.1136/gutjnl-2025-336714) - Götte M. *Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance*. Current opinion in virology. 2014. [PubMed 25128987](https://doi.org/10.1016/j.coviro.2014.07.010) - Feld JJ. *Interferon-free strategies with a nucleoside/nucleotide analogue*. Seminars in liver disease. 2014. [PubMed 24782257](https://doi.org/10.1055/s-0034-1371009) - Shannon A et al. *An exonuclease-resistant chain-terminating nucleotide analogue targeting the SARS-CoV-2 replicase complex*. [Nucleic acids research](/blog/news/nucleic-acids-research). 2024. [PubMed 38096103](https://doi.org/10.1093/nar/gkad1194) - Furuhata T et al. *Highly Conductive Nucleotide Analogue Facilitates Base-Calling in Quantum-Tunneling-Based DNA Sequencing*. ACS nano. 2019. [PubMed 30888791](https://doi.org/10.1021/acsnano.9b01250) ## Related Topics - [Nucleotide Structure](/knowledge/molecular-biology/nucleotide-structure) - [Nucleotide Sequence](/knowledge/molecular-biology/nucleotide-sequence) - [Nucleotide Base](/knowledge/molecular-biology/nucleotide-base) - [Nucleotide Examples](/knowledge/molecular-biology/nucleotide-examples) - [Nucleotide Nucleoside](/knowledge/molecular-biology/nucleotide-nucleoside)
## Related Clinical & Scientific Guides * [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway) * [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor) * [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)